Steven Cohen's CNTA Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 307,355 shares of Centessa Pharmaceuticals plc (CNTA) worth $12.21 M, representing 0.02% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in CNTA, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2023, adding 1.7 M shares. Largest reduction occurred in Q3 2025, reducing 1.52 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Centessa Pharmaceuticals plc (CNTA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Centessa Pharmaceuticals plc (CNTA) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +307,355 | New Buy | 307,355 | $39.72 |
| Q4 2025 | -1.07 M | Sold Out | 0 | $0.00 |
| Q3 2025 | -1.52 M | Reduce 58.61% | 1.07 M | $24.25 |
| Q2 2025 | +305,163 | Add 13.35% | 2.59 M | $13.14 |
| Q1 2025 | -1.14 M | Reduce 33.27% | 2.29 M | $14.38 |
| Q4 2024 | +710,936 | Add 26.18% | 3.43 M | $16.75 |
| Q3 2024 | +953,659 | Add 54.12% | 2.72 M | $15.99 |
| Q2 2024 | -495,714 | Reduce 21.96% | 1.76 M | $9.03 |
| Q1 2024 | +417,236 | Add 22.67% | 2.26 M | $11.30 |
| Q3 2023 | -170,906 | Reduce 8.50% | 1.84 M | $6.47 |
| Q2 2023 | +235,906 | Add 13.29% | 2.01 M | $6.19 |
| Q1 2023 | +1.7 M | Add 2127.71% | 1.78 M | $3.85 |
| Q4 2022 | -38,100 | Reduce 32.34% | 79,700 | $3.10 |
| Q3 2022 | -15,800 | Reduce 11.83% | 117,800 | $4.02 |
| Q2 2022 | -773,400 | Reduce 85.27% | 133,600 | $4.87 |
| Q1 2022 | -190,908 | Reduce 17.39% | 907,000 | $8.97 |
| Q4 2021 | +795,708 | Add 263.31% | 1.1 M | $11.26 |
| Q3 2021 | +202,200 | Add 202.20% | 302,200 | $16.70 |
| Q2 2021 | +100,000 | New Buy | 100,000 | $22.21 |
Steven Cohen's Centessa Pharmaceuticals plc Investment FAQs
Steven Cohen first purchased Centessa Pharmaceuticals plc (CNTA) in Q2 2021, acquiring 100,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Centessa Pharmaceuticals plc (CNTA) for 20 quarters since Q2 2021.
Steven Cohen's largest addition to Centessa Pharmaceuticals plc (CNTA) was in Q1 2023, adding 1,775,482 shares worth $6.84 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 307,355 shares of Centessa Pharmaceuticals plc (CNTA), valued at approximately $12.21 M.
As of the Q1 2026 filing, Centessa Pharmaceuticals plc (CNTA) represents approximately 0.02% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Centessa Pharmaceuticals plc (CNTA) was 3,426,599 shares, as reported at the end of Q4 2024.